Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PEPG
- Price
- 1.45
- Stock movement up
- +0.02 (1.63%)
- Company name
- PepGen Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 41.00M
- Ent value
- 31.49M
- Price/Sales
- 24.70
- Price/Book
- 0.30
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -87.28%
- 3 year return
- -51.07%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-09-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
PEPG does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 24.70 |
| Price to Book | 0.30 |
| EV to Sales | 18.97 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 32.80M |
| EPS (TTM) | -2.68 |
| FCF per share (TTM) | -2.54 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.66M |
| Gross profit (TTM) | 560.00K |
| Operating income (TTM) | -94.20M |
| Net income (TTM) | -87.23M |
| EPS (TTM) | -2.68 |
| EPS (1y forward) | -1.80 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 33.73% |
| Operating margin (TTM) | -5675.00% |
| Profit margin (TTM) | -5255.06% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 42.29M |
| Net receivables | 0.00 |
| Total current assets | 142.37M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 28.58M |
| Total assets | 170.23M |
| Accounts payable | 5.93M |
| Short/Current long term debt | 19.04M |
| Total current liabilities | 16.81M |
| Total liabilities | 32.78M |
| Shareholder's equity | 137.46M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -82.32M |
| Capital expenditures (TTM) | 453.00K |
| Free cash flow (TTM) | -82.77M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -63.46% |
| Return on Assets | -51.24% |
| Return on Invested Capital | -62.08% |
| Cash Return on Invested Capital | -58.90% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.23 |
| Daily high | 1.27 |
| Daily low | 1.20 |
| Daily Volume | 268K |
| All-time high | 18.55 |
| 1y analyst estimate | 7.00 |
| Beta | 1.19 |
| EPS (TTM) | -2.68 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 6 Nov 2025 |
Downside potential
Loading...
Downside potential data
| PEPG | S&P500 | |
| Current price drop from All-time high | -93.26% | -1.46% |
| Highest price drop | -94.61% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -45.92% | -10.99% |
| Avg time to new high | 69 days | 12 days |
| Max time to new high | 329 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
41.00M
Marketcap category
Small-cap
Description
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
Employees
62
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page